Skip to main content

Nasal polyposis and the role of alphintern

Abstract

Introduction

Nasal polyposis is a chronic inflammatory disease of the nasal mucosa. The pathogenesis of nasal polyps is still not entirely known. This makes definitive treatment very challenging. The aim of our study is to evaluate the effect of alphintern on the treatment of nasal polyposis.

Patients and methods

Patients received alphintern tablet for 2 weeks. Before and after drug intake all patients were asked to fill in a questionnaire in which they rated their overall symptoms on visual analog scale; endoscopic physical findings were scored on the Lindholdt staging system.

Results

Twenty-three patients were included in the study, 14 men and nine women in the age range from 25 to 56 years. Statistical analysis shows no significant difference (P>0.05) before and after treatment with alphintern for severity of symptoms and endoscopic staging of nasal polyposis.

Discussion

The main goals in the treatment of nasal polyposis, whether medical or surgical, are to relief patient symptoms and to prevent complications. There are few direct comparisons of the medical and surgical treatment in the literature. Those that exist suggest that most patients should be treated medically, with surgery reserved for patients who respond poorly. Intranasal corticosteroids are by far the best documented type of medical treatment for nasal polyposis. Researches for other drugs for the treatment of nasal polyposis were done. In this study, the use of alphintern for the treatment of nasal polyposis shows no significant improvement in the severity of symptoms and size of polyps.

Conclusion

Topical intranasal steroids are the best documented medical treatment. Alphintern shows no significant effect on the management of nasal polyposis. Further studies with more patients and longer duration of treatment are required for more evaluation of drug effect.

References

  1. 1

    Olejniczak I, Kobos J, Gryczyński M, Durko M, Pietruszewska W. Expression of adhesion molecule ICAM-1 in patients with nasal polyps. Otolaryngol Pol 2007; 61:607–611.

    Article  Google Scholar 

  2. 2

    Norès JM, Avant P, Bonfils P. Sino-nasal polyposi. Evaluation of the efficacy of combined local and general corticotherapy in a series of 100 consecutive patients with a 3-year follow-up. Bull Acad Natl Med 2002; 186:1643–1656.

    Google Scholar 

  3. 3

    Figueiredo CR, Silva ID, Weckx LL. Inflammatory genes in nasal polyposis. Curr Opin Otolaryngol Head Neck Surg 2008; 16:18–26.

    Article  Google Scholar 

  4. 4

    Penn R, Mikula S. The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study. Am J Rhinol 2007; 21:428–432.

    Article  Google Scholar 

  5. 5

    Gillespie MB, Osguthorpe JD. Pharmacologic management of chronic rhinosinusitis, alone or with nasal polyposis. Curr Allergy Asthma Rep 2004; 4:478–485.

    Article  Google Scholar 

  6. 6

    Scadding GK. Comparison of medical and surgical treatment of nasal polyposis. Curr Allergy Asthma Rep 2002; 2:494–499.

    Article  Google Scholar 

  7. 7

    Toros SZ, Bölükbasi S, Naiboğlu B, Er B, Akkaynak C, Noshari H, Egeli E. Comparative outcomes of endoscopic sinus surgery in patients with chronic sinusitis and nasal polyps. Eur Arch Otorhinolaryngol 2007; 264:1003–1008.

    Article  Google Scholar 

  8. 8

    Johansson L, Akerlund A, Holmberg K, Melén I, Stierna P, Bende M. Evaluation of methods for endoscopic staging of nasal polyposis. Acta Otolaryngol 2000; 120:72–76.

    Article  CAS  Google Scholar 

  9. 9

    Norès JM, Avan P, Bonfils P. Medical management of nasal polyposis: a study in a series of 152 consecutive patients. Rhinology 2003; 41:97–102.

    PubMed  Google Scholar 

  10. 10

    Mygind N, Valerie J. Nasal polyposis. In: Michael G, George G, Martin J, et al. editors. Scott-Brown’s otolaryngology, head and neck surgery. 7th ed. Great Britain: Hodder Arnold 2008. pp. 1549–1559.

    Google Scholar 

  11. 11

    Payman D, Jalal M, Shahin B, Ali M, Zahra M. The efficacy of clarithromycin in patients with severe nasal polyposis. Acta Med Iran 2013; 51:6.

    Google Scholar 

  12. 12

    Kieff DA, Busaba NY. Efficacy of montelukast in the treatment of nasal polyposis. Ann Otol Rhinol Laryngol 2005; 114:941–945.

    Article  Google Scholar 

  13. 13

    Haye R, Aanesen JP, Burtin B, Donnelly F, Duby C. The effect of cetirizine on symptoms and signs of nasal polyposis. J Laryngol Otol 1998; 112:1042–1046.

    Article  CAS  Google Scholar 

  14. 14

    Kroflic B, Coer A, Baudoin T, Kalogjera L. Topical furosemide versus oral steroid in preoperative management of nasal polyposis. Eur Arch Otorhinolaryngol 2006; 263:767–771.

    Article  Google Scholar 

  15. 15

    Helbling A, Baumann A, Hänni C, Caversaccio M. Amphotericin B nasal spray has no effect on nasal polyps. J Laryngol Otol 2006; 120:1023–1025.

    Article  CAS  Google Scholar 

  16. 16

    Morley AD, Sharp HR. A review of sinonasal outcome scoring systems-which is best? Clin Otolaryngol 2006; 31:103–109.

    Article  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Agila Al-Barasi.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Al-Barasi, A. Nasal polyposis and the role of alphintern. Egypt J Otolaryngol 35, 246–249 (2019). https://doi.org/10.4103/ejo.ejo_7_19

Download citation

Keywords

  • alphintern
  • intranasl steroids
  • nasal polyposis